1 positive) charge on the catalytic domain and bacteriolytic activity in the absence of the CBD (noncla

2                                              Bacteriolytic activity, as well as strong interactions b

3                         PGRP-L has no direct bacteriolytic activity.

4 ite and are identified to be crucial for its bacteriolytic activity.

5                                   CF-301 was bacteriolytic against 250 S. aureus strains tested inclu

6 th and LYZL2 (p value = 9e-9), which codes a bacteriolytic agent thought to be involved in host defen

7                                              Bacteriolytic anti-cancer therapies employ attenuated ba

8                   However, the generality of bacteriolytic effectors and, moreover, of antibacterial

9 uced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate la

10 lement proteins C3b and C5 and inhibited the bacteriolytic effects of complement.

11 s because of its potent, specific, and rapid bacteriolytic effects.

12 phylococcus simulans secretes lysostaphin, a bacteriolytic enzyme that cleaves staphylococcal peptido

13 phylococcus simulans secretes lysostaphin, a bacteriolytic enzyme that specifically binds to the cell

14                          Lysozyme (LYS) is a bacteriolytic enzyme, available in secretions such as sa

15                PGRP was not a PGN-lytic or a bacteriolytic enzyme, but it inhibited the growth of Gra

16 me in a bacteriophage infective cycle, allow bacteriolytic enzymes, or endolysins, to escape to the p

17 ons to confer target cell specificity to the bacteriolytic molecule.

18  response is triggered by membrane-targeting bacteriolytic peptides of different structural classes a

19            This strategy, called combination bacteriolytic therapy (COBALT), has the potential to add